ABBOTINDIA:NSE-Abbott India Limited (INR)

COMMON STOCK | Drug Manufacturers—General | NSE

Last Closing Price

INR 15,723.40

Change

+65.95 (+0.42)%

Market Cap

INR 345.28B

Volume

0.01M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Abbott India Limited operates as a pharmaceutical company in India. It offers pharmaceutical products for various therapeutic areas, such as women's health, gastroenterology, metabolics, central nervous system, pain management, nutritional supplements, vitamins, insomnia, vaccines, consumer health, etc. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. Abbott India Limited was founded in 1944 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Laboratories

Employees : 3,485

Currency: INR

Country : India

Technical Indicators

Beta : -0.04

52 Week High : 18,679.75

52 Week Low : 8,278.00

200 Day Moving Average : 15,075.81

50 Day Moving Average : 16,675.87

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-06 )

Largest Industry Peers for Drug Manufacturers—General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CIPLA:NSE Cipla Limited

-4.20 (-0.66%)

 INR511.30B 31.73 14.72
GLAXO:NSE GlaxoSmithKline Pharmaceutical..

+16.70 (+1.14%)

 INR256.84B 239.20 54.53
SANOFI:NSE Sanofi India Limited

-199.00 (-2.55%)

 INR189.37B 47.00 26.51
PFIZER:NSE Pfizer Limited

-16.00 (-0.39%)

 INR187.30B 35.42 20.54
MARKSANS:NSE Marksans Pharma Limited

N/A

 INR14.82B 18.02 10.71
SMSPHARMA:NSE SMS Pharmaceuticals Limited

-1.15 (-1.79%)

 INR5.18B 14.57 8.03
KILITCH:NSE Kilitch Drugs (India) Limited

-0.45 (-0.48%)

 INR1.60B 63.98 19.11
KOPRAN:NSE Kopran Limited

-0.25 (-0.74%)

 INR1.54B 6.73 4.86

ETFs Containing ABBOTINDIA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—General)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.66% 67% D+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.66% 67% D+ 80% B-
Trailing 12 Months  
Capital Gain 76.83% 89% B+ 95% A
Dividend Return 0.56% 75% C 33% F
Total Return 77.39% 100% A+ 95% A
Trailing 5 Years  
Capital Gain 289.40% 100% A+ 96% A
Dividend Return 5.10% 63% D 50% F
Total Return 294.50% 100% A+ 96% A
Average Annual (5 Year Horizon)  
Capital Gain 32.23% 83% B 77% C+
Dividend Return 0.79% 64% D 56% F
Total Return 33.02% 83% B 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 40.09% 42% F 64% D
Risk Adjusted Return 82.37% 83% B 92% A-
Market Capitalization 345.28B 89% B+ 95% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—General)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 56.17 33% F 8% F
Price/Book Ratio 15.68 11% F 2% F
Price / Cash Flow Ratio 55.15 33% F 5% F
EV/EBITDA 35.67 22% F 7% F
Management Effectiveness  
Return on Equity 26.71% 100% A+ 93% A
Return on Invested Capital -20.89% 11% F 4% F
Return on Assets 13.43% 100% A+ 95% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.04 100% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.